<DOC>
	<DOCNO>NCT00003829</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Alternating treatment one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness fludarabine alternate cyclophosphamide treat patient previously untreated chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine rate duration complete partial remission patient previously untreated B-cell chronic lymphocytic leukemia treatment alternate course fludarabine cyclophosphamide . II . Monitor assess toxicity regimen patient . III . Utilize molecular genetic study flow cytometry peripheral blood cell patient achieve complete remission conventional criterion . IV . Apply FISH technique use probe chromosomes 12 13 prognostic factor time progression overall survival patient . OUTLINE : Patients receive alternate course fludarabine cyclophosphamide . Fludarabine administer IV 10-30 minute day 1-5 course 1 , 3 , 5 . Cyclophosphamide administered IV 30-60 minute day 1 course 2 , 4 , 6 . Treatment repeat every 4 week . Patients achieve clinical complete remission ( CCR ) 6 course chemotherapy receive 2 additional course ( one course drug ) . Patients achieve partial remission 6 course chemotherapy also receive 2 additional course . If patient achieve CCR , receive another 2 course . Patients follow every 3 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell chronic lymphocytic leukemia ( CLL ) manifest follow : Threshold peripheral lymphocyte count great 5000/mm3 Small moderate peripheral lymphocyte great 55 % prolymphocytes Peripheral lymphocyte count le 15,000/mm3 At least 30 % lymphoid cell bone marrow Monoclonality B lymphocytes Active disease least one follow criterion : Weight loss least 10 % within past 6 month prolong fever night sweat without evidence infection Progressive marrow failure ( stage III IV disease ) manifest Hemoglobin le 11 g/dL ( anemia ) AND/OR Platelet count le 100,000/mm3 ( thrombocytopenia ) Autoimmune anemia and/or thrombocytopenia minimally responsive corticosteroid therapy Massive progressive splenomegaly Massive progressive lymphadenopathy Progressive lymphocytosis ( due effect corticosteroid ) Marked hypogammaglobulinemia development monoclonal protein absence criterion sufficient eligibility PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 1.5 time ULN ( unless due hemolysis CLL ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease No myocardial infarction past month Other : No uncontrolled infection No active infection HIV ( AIDS ) No malignancy within past 2 year except nonmelanomatous skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Prior interferon allow Chemotherapy : No prior cytotoxic chemotherapy Endocrine therapy : See Disease Characteristics Prior corticosteroid , somatostatin analogue , tamoxifen allow Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>